Keyphrases
SHP-1
86%
Taiwan
68%
CIP2A
65%
Induced Apoptosis
63%
Triple-negative Breast Cancer
54%
Breast Cancer
51%
Triple-negative Breast Cancer Cells
46%
Hepatocellular Carcinoma Cells
42%
Breast Cancer Patients
41%
Overall Survival
41%
Hepatocellular Carcinoma
37%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
36%
Protein Phosphatase 2A (PP2A)
35%
Taiwanese
34%
Prognostic Factors
33%
Rituximab
30%
Cholangiocarcinoma
29%
Risk Factors
28%
Sorafenib
27%
Chemotherapy
25%
Tumor
25%
Apoptosis
24%
Progression-free Survival
24%
Confidence Interval
23%
Diffuse Large B-cell Lymphoma (DLBCL)
23%
Overexpression
22%
P-STAT3
21%
Bortezomib
21%
Absolute Lymphocyte Count
21%
Multivariate Analysis
20%
Poor Prognosis
20%
SC-2001
20%
In Cancer
20%
Hematopoietic Stem Cell Transplantation
19%
Multiple Myeloma
19%
Putative Drug Targets
18%
Metastatic Breast Cancer
18%
Human Epidermal Growth Factor Receptor 2 (HER2)
18%
Obatoclax
17%
Genetic Modification
17%
Graft-versus-host Disease (GvHD)
17%
AKT1
16%
Human Breast Cancer Cells
16%
Erlotinib
16%
Soft Tissue Sarcoma
16%
Signal Transducer and Activator of Transcription 3
16%
Cancer Patients
16%
Hazard Ratio
16%
Patients with Breast Cancer
15%
Targeted Sequencing
15%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
92%
Liver Cell Carcinoma
70%
Neoplasm
43%
Triple Negative Breast Cancer
41%
Phosphoprotein Phosphatase 2A
40%
Sorafenib
39%
Bile Duct Carcinoma
37%
Overall Survival
32%
Chemotherapy
25%
Multiple Myeloma
25%
Rituximab
23%
Diseases
22%
Cohort Study
21%
Bortezomib
21%
Malignant Neoplasm
20%
Protein Kinase B
20%
Progression Free Survival
19%
Prevalence
19%
STAT3 Protein
18%
Obatoclax
17%
Diffuse Large B Cell Lymphoma
16%
Leukemia
15%
Hormone Receptor
15%
Paclitaxel
13%
Nonhodgkin Lymphoma
13%
Erlotinib
12%
Regorafenib
12%
Anemia
11%
Cyclin Dependent Kinase 4
11%
Metastatic Breast Cancer
10%
Palbociclib
10%
Docetaxel
10%
Protein Tyrosine Phosphatase SHP 1
10%
Hepatitis B Virus
10%
Infection
9%
Gamma Urogastrone
9%
Chronic Graft Versus Host Disease
9%
Side Effect
9%
Hematologic Disease
9%
Hepatitis B
8%
Trastuzumab
8%
Adverse Event
8%
Clinical Trial
8%
Graft Versus Host Reaction
8%
Hematologic Malignancy
8%
Death Receptor 5
8%
Tumor Growth
8%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
8%
Neutropenia
8%
Epidermal Growth Factor Receptor
8%
Medicine and Dentistry
Breast Cancer
100%
Neoplasm
55%
Overall Survival
44%
Prognostic Factor
34%
Triple Negative Breast Cancer
31%
Cancer Cell
30%
Hematopoietic Stem Cell Transplantation
27%
Programmed Cell Death
27%
Diseases
26%
Progression Free Survival
23%
Malignant Neoplasm
21%
Cohort Analysis
21%
Soft Tissue Sarcoma
20%
Metastatic Carcinoma
19%
Hormone Receptor
17%
Gamma Urogastrone
17%
Platelet
17%
Prevalence
17%
Cholangiocarcinoma
16%
Diffuse Large B-Cell Lymphoma
16%
Rituximab
15%
Cancer
15%
Multivariate Analysis
15%
Epidermal Growth Factor Receptor 2
14%
Multiple Myeloma
14%
Hazard Ratio
14%
Lymphocyte
13%
Anemia
12%
4 Iodo 2,5 Dimethoxyamphetamine
12%
Brain Metastasis
12%
BRCA1
11%
Recurrent Disease
11%
Phosphoprotein Phosphatase 2A
11%
Metastatic Breast Cancer
10%
Infection
9%
Disease Free Survival
9%
Cancer of Unknown Primary Origin
9%
Proportional Hazards Model
9%
CDK4/6 Inhibitor
8%
Estrogen Receptor
8%
Systemic Therapy
8%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
8%
Chronic Graft Versus Host Disease
8%
Cell Count
8%
Diabetes Mellitus
8%
Candidemia
8%
Imatinib
8%
Tamoxifen
8%
Anoikis
8%
Autologous Stem Cell Transplantation
8%